Gilead’s Kite jumps back to the bargaining table to forge $875M pact with a newly-emerged upstart on next-gen cell therapies

Just 6 weeks after striking a $2.3 billion deal to develop off-the-shelf cell therapies with Shoreline Biosciences, Gilead sub Kite Pharma …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Gilead’s Kite jumps back to the bar­gain­ing ta­ble to forge $875M pact with a new­ly-emerged up­start on next-gen cell ther­a­pies